Cedars-Sinai Cancer | Strategic Alliance Partners

Cedars-Sinai Cancer in Los Angeles serves one of the most diverse regions globally. Ranked No. 7 for cancer by U.S. News & World Report 2020-2021, the center’s clinicians are committed to providing compassionate, state-of-the-art care, while its scientists are carrying out the latest translational research and groundbreaking advances. The cancer enterprise includes the Samuel Oschin Comprehensive Cancer Institute, The Angeles Clinic and Research Institute, Tower Hematology Oncology Medical Group, Torrance Memorial Hunt Cancer Center and Cedars-Sinai Tarzana.

Latest from Cedars-Sinai Cancer

Dr Freedland on the Increasingly Prominent Role of Enzalutamide in Prostate Cancer Treatment

December 01, 2025

Video

Stephen Freedland, MD, discusses how findings from the phase 3 EMBARK trial suggest a new standard of care in prostate cancer.

Dr Freedland on the Efficacy Results From the EMBARK Trial of Enzalutamide in Prostate Cancer

November 24, 2025

Video

Stephen Freedland, MD, discusses how the efficacy findings of each arm of the phase 3 EMBARK trial in prostate cancer stacked up with one another.

Five Under 5: Top Oncology Videos for the Week of 11/16

November 23, 2025

Article

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Dr Freedland on the Rationale Behind the EMBARK Trial in Prostate Cancer

November 18, 2025

Video

Stephen Freedland, MD, discusses the rationale for conducting the phase 3 EMBARK trial evaluating enzalutamide plus leuprolide in high-risk prostate cancer.

ADC and CDK4/6 Inhibitor Research Set to Refine TNBC and ER+ Breast Cancer Treatment Strategies

November 04, 2025

Article

Yuan Yuan, MD, PhD, discusses the use of sacituzumab govitecan in TNBC and remaining questions about the use of CDK4/6 inhibitors in ER-positive disease.

Dr Reckamp on the Future Implications of the PRAGMATICA-LUNG Trial in Lung Cancer

July 26, 2025

Video

Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for May 2025

May 30, 2025

Article

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer

October 08, 2024

Article

Yuan Yuan, MD, PhD, discusses post-CDK4/6 inhibitor treatment options for HR-positive breast cancer and expansions of the definition of HER2 expression.

Research Seeks to Establish the Efficacy of Minimally Invasive Breast Cancer Procedures and Tests

October 05, 2024

Article

Yuan Yuan, MD, PhD, discusses the management of node-positive breast cancer and the need for guidance surrounding the use of ctDNA in breast cancer.

Dr Yuan on the Evolution of Radiation Therapy Approaches in Breast Cancer

September 17, 2024

Video

Yuan Yuan, MD, PhD, discusses radiation therapy approaches across various of breast cancer subtypes.

Dr Yuan on the Investigation of Adjuvant CDK4/6 Inhibition in Breast Cancer

September 16, 2024

Video

Yuan Yuan, MD, PhD, discusses key research evaluating adjuvant CDK4/6 inhibition in breast cancer.

Dr Gong on the Benefits and Limitations of PARP Inhibitor–Based Regimens in mCRPC

July 25, 2024

Video

Jun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.

Final Thoughts on CSPC

July 17, 2024

Video

Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.

Patient Case 2: Metastatic CSPC

July 17, 2024

Video

Key opinion leaders outline a case study of a patient with metastatic castration-sensitive prostate cancer, detailing the chosen treatment approaches and the overall outcome of the case.

Dr Gong on the Importance of Molecular Profiling in mCRPC

July 15, 2024

Video

Jun Gong, MD, discusses the importance of molecular profiling when determining optimal treatments for patients with mCRPC.

Dr Gong on the Frontline Use of PARP Inhibitors in mCRPC

June 28, 2024

Video

Jun Gong, MD, discusses the variety of PARP inhibitor–based frontline treatment regimens that are FDA approved for patients with mCRPC.

Dr Freedland on Implications of Treatment Suspension on HRQOL in High-Risk nmHSPC

June 26, 2024

Video

Stephen J. Freedland, MD, discusses the effects of treatment suspension on HRQOL in nonmetastatic hormone-sensitive prostate cancer in the EMBARK trial.

Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs

June 20, 2024

Podcast

Dr Reckamp discusses the definition of pragmatic clinical trials and ways that clinical trial investigators can make their research more pragmatic.

Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC

May 04, 2024

Article

Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

April 15, 2024

Podcast

Drs Camidge and Rimel spotlight Dr Rimel’s career journey and the work she does to expand medical care for transgender patients.